Literature DB >> 15909060

Relationship of international normalized ratio to bleeding and thromboembolism rates in Taiwanese patients receiving vitamin K antagonist after mechanical valve replacement.

Hsi-Yu Yu1, Chih-Ho Liu, Yih-Sharng Chen, Shoei-Shen Wang, Shu-Hsun Chu, Fang-Yue Lin.   

Abstract

BACKGROUND AND
PURPOSE: Asians may be less vulnerable to thrombotic disease than Caucasians. Optimum international normalized ratio (INR) anticoagulant therapy guidelines for Asian populations remain to be established. This study investigated the risk factors for major bleeding or thromboembolism (TE) in Taiwanese patients receiving mechanical aortic and/or mitral valve replacement, including INR < or > 2.0.
METHODS: The records of 563 Taiwanese patients receiving mechanical aortic and/or mitral valve replacement between 1996 and 2001 were retrospectively studied. Patient follow-up data was divided into several 6-month periods: 6-month increments after surgery if no bleeding or TE occurred and the 6 months preceding the adverse event when an event occurred. Data including warfarin sodium dosage and estimated INR unit for each time period were collected and analyzed.
RESULTS: A total of 3,391 records were retrieved for analysis with an average follow-up period of 3.3 +/- 1.4 years. The mean warfarin sodium dose was 2.86 +/- 1.09 mg/day and the INR was 1.86 +/- 0.66. Major bleeding events occurred in 20 patients (1.07% per patient-year) and TE events in 38 patients (2.04% per patient-year), accounting for a 3.11% rate of overall events (bleeding or TE) per patient-year. Multivariate risk analysis revealed follow-up age > 60 years and receiving mitral valve replacement were risk factors for overall events (odds ratio = 1.84, p = 0.021 for follow-up age > 60 years; odds ratio = 1.36, p = 0.019 for receiving mitral valve replacement), while gender, double valve replacement, valve type, INR < 2.0, and atrial fibrillation were not.
CONCLUSIONS: Our data suggest that low-intensity anticoagulant therapy (INR < 2.0) in Taiwanese patients was not associated with increased TE and bleeding rates compared to higher intensity anticoagulant therapy. Follow-up age over 60 years and valve replacement at the mitral site were associated with increased rate of overall events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15909060

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  7 in total

Review 1.  Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.

Authors:  Julie A Johnson
Journal:  Circulation       Date:  2008-09-23       Impact factor: 29.690

2.  Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia.

Authors:  Frances Edwards; Paul Arkell; Lesley M Roberts; David Gendy; Christina Siew-Hie Wong; Joanna Chee Yien Ngu; Lee Len Tiong; Faridha Mohd Salleh Bibi; Lana Yin Hui Lai; Tiong Kiam Ong; Michael Abouyannis
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

3.  Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system.

Authors:  Shu-Wen Lin; Wen-Yi Kang; Dong-Tsamn Lin; James Lee; Fe-Lin Wu; Chuen-Liang Chen; Yufeng J Tseng
Journal:  BMC Med Genomics       Date:  2014-05-08       Impact factor: 3.063

4.  Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy.

Authors:  Chin-Wei Hsu; Yaw-Bin Huang; Chen-Chun Kuo; Chung-Yu Chen
Journal:  Biomed Res Int       Date:  2016-11-21       Impact factor: 3.411

5.  Tranexamic acid reduces postoperative blood loss in Chinese pediatric patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Zhi-Yao Zou; Li-Xian He; Yun-Tai Yao
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

6.  Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery(*).

Authors:  Feridoun Sabzi; Gholam Reza Moradi; Heidar Dadkhah; Alireza Poormotaabed; Samsam Dabiri
Journal:  J Res Med Sci       Date:  2012-01       Impact factor: 1.852

Review 7.  Is hyperlipidemia a potential protective factor against intraoperative awareness in cardiac surgery?

Authors:  Qingshui Zheng; Qian Wang; Chaoqun Wu; Zhifa Wang; Hushan Ao
Journal:  J Cardiothorac Surg       Date:  2016-04-12       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.